Core Viewpoint - Company Tong Ren Tang has received a Traditional Medicine Registration License from the Ministry of Health of the Kingdom of Cambodia, allowing the sale of "Tong Ren Tang An Gong Niu Huang Wan" in Cambodia, which will enhance the distribution channels for the company's key products and support market expansion [1] Group 1 - The license permits the sale of "Tong Ren Tang An Gong Niu Huang Wan" under the guidance of licensed traditional Chinese medicine practitioners [1] - The Ministry of Health of Cambodia had previously issued an import license for "Tong Ren Tang An Gong Niu Huang Wan" [1] - The acquisition of the license will not have a significant immediate impact on the company's production operations and performance [1] Group 2 - The sales of the medicine may be influenced by changes in Cambodia's policy environment, exchange rate fluctuations, and market competition [1]

智通财经APP讯，同仁堂国药(03613)发布公告，公司于近日收到柬埔寨王国(柬埔寨)卫生部药品与食品 司颁发的《传统药品注册许可证》("许可证")，准许将公司的"同仁堂安宫牛黄丸"在柬埔寨出售。 "同仁堂安宫牛黄丸"应遵照持证的中医师的指导下使用。另外，早前柬埔寨卫生部亦已颁发"同仁堂安 宫牛黄丸"进口许可证。 本次公司取得柬埔寨卫生部药品与食品司签发的许可证后，公司的"同仁堂安宫牛黄丸"可在柬埔寨出 售，有助于丰富公司重点产品的分销渠道，有利于公司的市场拓展。上述许可证的取得暂不会对公司生 产经营和业绩产生重大影响。药品销售容易受到柬埔寨政策环境变化、汇率波动、市场竞争等因素的影 响。 ...

格隆汇9月26日丨同仁堂国药(03613.HK)发布公告，公司于近日收到柬埔寨卫生部药品与食品司颁发的 《传统药品注册许可证》，准许将公司的"同仁堂安宫牛黄丸"在柬埔寨出售。本次本公司取得柬埔寨卫 生部药品与食品司签发的许可证后，公司的"同仁堂安宫牛黄丸"可在柬埔寨出售，有助于丰富公司重点 产品的分销渠道，有利于公司的市场拓展。 ...

Core Viewpoint - The company has received a Traditional Medicine Registration License from the Ministry of Health of the Kingdom of Cambodia, allowing the sale of "Tong Ren Tang An Gong Niu Huang Wan" in Cambodia, which will enhance distribution channels and market expansion [1] Group 1 - The registration number for the product is CAM N0004IT-25, and the license is valid until September 11, 2028 [1] - This license acquisition is expected to enrich the company's key product distribution channels [1] - The move is beneficial for the company's market expansion efforts [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責 ， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明 ， 並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任 。 BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED 北 京 同 仁 堂 國 藥 有 限 公 司 （ 於 香 港 註 冊 成 立 之 有 限 公 司 ） （ 股 份 代 號 ： 3613） 自 願 公 告 獲 發 傳 統 藥 品 註 冊 許可證 本公告由 北 京 同 仁 堂 國 藥 有 限 公 司 （ 「 本 公 司 」 ） 之 董 事 會 （ 「 董 事 會 」 ） 自 願 作 出 ， 旨 在 向 其 股 東 和 潛 在 投 資 者 提 供 有 關 本 公 司 最 新 業 務 發 展 。 董 事 會 欣 然 宣 佈 ， 本 公 司 於 近 日 收 到 柬埔 ...

Group 1 - The core point of the article is the announcement of leadership changes at Tong Ren Tang Guo Yao (03613.HK) due to the retirement of Gu Haiou [1] - Gu Haiou will retire as Executive Director, Chairman of the Board, and Authorized Representative effective September 4, 2025 [1] - Yan Han has been appointed as the new Chairman of the Board, while Le Zheng has been appointed as the Authorized Representative, both effective from the same date [1]

Beijing Tong Ren Tang Chinese Medicine Company Limited 北京同仁堂國藥有限公司 (Incorporated in Hong Kong with limited liability) ( 於香港註冊成立之有限公司 ) (Stock Code / 股份代號: 3613) N O T I F I C AT I O N L E T T E R 通 知 信 函 As a non-registered shareholder, if you wish to receive Actionable Corporate Communication (Note 2) from the Company pursuant to the Listing Rules, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares are held (collectively, the "Interm ...

Group 1 - The announcement states that Gu Haiou will retire from his positions as Executive Director, Chairman of the Board, and Authorized Representative effective September 4, 2025, due to reaching retirement age [1] - Yan Han, currently an Executive Director, has been appointed as the new Chairman of the Board, effective September 4, 2025 [1] - Le Zheng, also an Executive Director and Vice Chairman, has been appointed as the Authorized Representative, effective September 4, 2025 [1]

Pursuant to Rules 2.07A and 2.07B of the Rules Governing The Listing of Securities on the Stock Exchange under the expansion of paperless listing regime and electronic dissemination of Corporate Communications that came into effect on 31 December 2023, and in compliance with the new articles of association of the Company and the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (together with the Companies (Amendment) Ordinance 2025 that came into effect on 17 April 2025), the Company is writing to ...

Group 1 - The core point of the article is the announcement of leadership changes at Tong Ren Tang Chinese Medicine (03613), with Gu Haiou retiring and new appointments being made [1] - Gu Haiou will retire as Executive Director and Chairman of the Board effective September 4, 2025, due to reaching retirement age [1] - Yan Han has been appointed as the new Chairman of the Board, effective September 4, 2025 [1] - Le Zheng has been appointed as the authorized representative of the company, effective September 4, 2025 [1]